COMMUNIQUÉS West-GlobeNewswire

Pacific Biosciences Releases Highest-Quality, Most Contiguous Individual Human Genome Assembly to Date
08/10/2018
Diploid Assembly of a Puerto Rican Female Adds a Rich Resource to Population-Specific Reference Genomes MENLO PARK, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the [...]
Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
08/10/2018
Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 PHILADELPHIA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene [...]
FSD Pharma: Strategic Investments & Clean Balance Sheet -- CFN Media
08/10/2018
SEATTLE, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
TG Therapeutics, Inc. Highlights Schedule of Events at the Upcoming 34th Congress of ECTRIMS
08/10/2018
Final ublituximab phase 2 Multiple Sclerosis data to be featured in an oral presentation, Thursday, October 11, 2018, 16:51-17:03 CEST ECTRIMS data review conference call to be held Thursday, October 11, 2018, 19:30 [...]
Assertio Therapeutics to Report Third-Quarter 2018 Financial Results After The Close of Markets on Thursday, November 8, 2018
08/10/2018
LAKE FOREST, Ill., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2018 financial results on Thursday, November 8, 2018, after the close of [...]
PhaseBio Launches Roadshow for Initial Public Offering
08/10/2018
MALVERN, Pa. and SAN DIEGO, Oct. 08, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies [...]
Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies
08/10/2018
Collaboration Focuses on Four Genetic Disorders: Pompe, Fabry, CDKL5 and One Additional Undisclosed Rare Metabolic Disorder Combines Amicus Expertise in Protein Engineering with Penn’s AAV Vector Technology, [...]
Cancer Genetics and Cellaria Partner on Precision Medicine Tools
08/10/2018
Collaboration focused on developing pharmacology models to support biopharma R&D RUTHERFORD, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno [...]
Recro Pharma Announces PDUFA Date for IV Meloxicam
08/10/2018
PDUFA Date Set for March 24, 2019 MALVERN, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and [...]
Inspire Medical Systems, Inc. Announces First Implant of New Sensing Lead in Europe
08/10/2018
MINNEAPOLIS, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]
Akcea Announces Changes to Board of Directors
08/10/2018
Dr. Damien McDevitt replaces Dr. Stanley Crooke on Akcea Board of Directors The change enhances focus on global approval and commercialization of TEGSEDI™ (inotersen) BOSTON, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akcea [...]
Transactions under Novozymes’ stock buyback program
08/10/2018
Please read the full announcement in the attached PDF Attachment 2018_57_Stock_Buybackprogram_EN
Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018
08/10/2018
XERAVA Demonstrated Efficacy in Treating Secondary Bacteremia in Patients with Complicated Intra-Abdominal Infections in Post-Hoc Analysis of Phase 3 Clinical Trials TP-6076 Demonstrated Favorable Pharmacokinetic and [...]
OraSure Technologies Earnings Conference Call Invitation
08/10/2018
2018 Third Quarter Earnings Conference Call Wednesday, November 7, 2018, 5:00 p.m. ET BETHLEHEM, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings [...]
Arrayit Corporation Aces Three Consecutive Rounds of Proficiency Testing with the College of American Pathologists
08/10/2018
Sunnyvale, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, reports that its clinical team aced three consecutive rounds of blinded-specimen [...]
Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2019
08/10/2018
The Annual General Meeting of 2018 decided that the Nomination Committee would be appointed as follows: "The Chairman of the Board shall convene the three largest shareholders in the Company, who each shall elect [...]
AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS
08/10/2018
Paris, October 8, 2018, 8.30am Research led by an international academic team reveals a novel pathogenic mechanism for ALS that can be therapeutically targeted by masitinib Results published in the Journal of Clinical [...]
AB Science la publication d'un mécanisme jusque-ici inconnu en lien avec la progression de la sclérose latérale amyotrophique (SLA) et qui corrobore l'effet protecteur du masitinib dans la SLA
08/10/2018
Paris, 8 octobre 2018, 8h30 Des recherches menées par une équipe universitaire internationale révèlent un nouveau mécanisme pathogène de la SLA pouvant être ciblé thérapeutiquement par le masitinib Les résultats publiés [...]
RAMSAY GENERALE DE SANTE : OPA CAPIO
08/10/2018
PRESS RELEASE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, OR SOUTH AFRICA. THE OFFER IS NOT BEING MADE TO (AND ACCEPTANCES [...]

Pages